VP

Vartika Paliwal

Active Director Director DIN 10656169
DIN 10656169 First appointment Jun 2024 Primary industry Paper
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2024
Shareholding value •••• Premium profile

About Vartika Paliwal

Data last updated:

Vartika Paliwal is a Director at Erudition Therapeutics Private Limited (since 2024). The company operates in Paper. Erudition Therapeutics Private Limited reported revenue of ₹2 Lakh (FY 2026).

DIN 10656169
Primary Designation Director
Industry Paper
First Appointment 04 Jun 2024
Oldest Company Age 2 yrs
Largest company Erudition Therapeutics Private Limited · ₹2 Lakh (FY 2026)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director04 Jun 20242024₹2 Lakh (FY 2026)Active

Board colleagues of Vartika Paliwal

Directorship timeline

Open interactive timeline →
Erudition Therapeutics Private Limited
Premium access

Shareholding and investment profile for Vartika Paliwal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vartika Paliwal

Vartika Paliwal currently holds 1 directorship: Erudition Therapeutics Private Limited (Director, since 04 Jun 2024, revenue ₹2 Lakh (FY 2026)).

Vartika Paliwal was first appointed on 04 Jun 2024 as Director at Erudition Therapeutics Private Limited.

The current boards of Vartika Paliwal's companies include Sarvesh Kumar Paliwal (Erudition Therapeutics Private Limited), Swapnil Sharma (Erudition Therapeutics Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available